Table 3.
Epitope prediction from confirmed peptide specificities on cervical samples
| PID | HIV protein | Net SFU/million cells | Peptide | HLA I epitope | HLA I type | HLA II epitope | HLA II type |
|---|---|---|---|---|---|---|---|
| 19 | p24 | 880 | 24 | 170PMFTALSEGATPQDLNTM187 | 170PMFTALSEGATPQDLNTM187 | ||
| 170PMFTALSEGATPQDLNTM187 | B42, B*4403 | ||||||
| p24 | 4680 | 25 | 178GATPQDLNTMLNTVGGH194 | B*3910, B*4201, B*8101, B*0702, Cw*0802 | 178GATPQDLNTMLNTVGGH194 | ||
| 2 | p24 | 5600 | 22 | 155WVKVIEEKAFSPEVIPMF172 | B*1503 | 155WVKVIEEKAFSPEVIPMF172 | DRB1*0101 |
| 155WVKVIEEKAFSPEVIPMF172 | B*4006 | 155WVKVIEEKAFSPEVIPMF172 | DQ5 | ||||
| 155WVKVIEEKAFSPEVIPMF172 | B*4501 | ||||||
| 155WVKVIEEKAFSPEVIPMF172 | B*4501 | ||||||
| 155WVKVIEEKAFSPEVIPMF172 | Cw*0602 | ||||||
| p24 | 2040 | 25 | 155WVKVIEEKAFSPEVIPMF172 | B57, B63 | 178GATPQDLNTMLNTVGGH194 | ||
| p24 | 6120 | 33 | 155WVKVIEEKAFSPEVIPMF172 | B63, B57, B58 | 234SDIAGTTSTLQEQIAWM250 | ||
| p2p7p1p6 | 680 | 57 | 155WVKVIEEKAFSPEVIPMF172 | B*35 | |||
| 178GATPQDLNTMLNTVGGH194 | B*3910, B*4201, B*8101, B*0702, Cw*0802 | ||||||
| 234SDIAGTTSTLQEQIAWM250 | B*5701, B*5703, B*5801 | ||||||
| 414WKCGKEGHQMKDCTERQA431 | A11 | ||||||
| 15 | p24 | 3210 | 25 | 178GATPQDLNTMLNTVGGH194 | B*3910, B*4201, B*8101, B*0702, Cw*0802 | 178GATPQDLNTMLNTVGGH194 | |
| 7 | p24 | 3820 | 23 | 163AFSPEVIPMFTALSEGA179 | 163AFSPEVIPMFTALSEGA179 | ||
| 163AFSPEVIPMFTALSEGA179 | B63, B57, B58 | ||||||
| 163AFSPEVIPMFTALSEGA179 | A*2601, A*2603 |
HLA, human leucocyte antigen; HIV, human immunodeficiency virus; PID, patient identity; SFU, spot-forming units. Previously defined immunodominant epitope are represented in bold.